MitoRx Therapeutics has strengthened its leadership team by appointing Alison Strutt as CFO, László Tankó as Consultant CMO, and Sam Fazeli as Non-Executive Director. These hires come as MitoRx prepares to advance its lead drug candidate, MTRX31, a novel small molecule targeting mitochondrial dysfunction in metabolically unhealthy obesity, into clinical development. MTRX31 has shown promising preclinical results, including significant weight loss and improved metabolic health, potentially offering a new approach to obesity treatment. The new leadership will support MitoRx’s growth and strategic efforts to bring this innovative therapy to patients at high risk of obesity-related diseases.
374Water Inc reported a 280% increase in Q2 revenue to $2.26 million, driven by progress in scaling its supercritical water oxidation technology for PFAS destruction. The company completed a key Factory Acceptance Test at Orange County Sanitation Dis...
Pinnacle Silver & Gold Corp announced promising assay results from its underground drilling at the Potrero gold-silver property in Durango, Mexico. Drilling at the historic Pinos Cuates mine extended the known mineralized strike length to at least 70...
AstraZeneca retained a 'buy' rating from Citi despite mixed updates on its drug pipeline. Positive Phase III trial results for Tagrisso plus Orpathys in lung cancer showed significant survival benefits, with Citi estimating $500 million in peak sales...
Apple is expected to launch a foldable iPhone alongside a refreshed Pro model in September 2026, with other variants following in early 2027. This new product could impact Apple's fiscal 2026 results and is already highly anticipated, with an 81% mar...
David Tepper's Appaloosa Management disclosed large Q2 positions in Apple, Taiwan Semiconductor Manufacturing (TSMC), and CoreWeave, each with distinct outlooks. Apple shows strong recent revenue and buybacks but faces valuation and margin risks, wit...
